A group of Japanese researchers announced on Friday that transplanted induced pluripotent stem cells (iPSs) in the brain of patients with Parkinson's disease, the first trial of this kind in the world.
Tim University of Kyoto inject 2.4 million iPS cells – capable of generating any kind of cell – in the left part of the brain during a three-hour operation in October.
The man, about 50 years old, has been well treated and remains under the supervision of two years, said in a statement at the University of Kyoto.
If a problem occurs in the next six months, researchers will implant 2.4 million additional cells, this time in the right part of the brain.
These iPS cells from healthy donors should be developed into neurons that produce dopamine, a neurotransmitter involved in engine control.
Kyoto University announced in July that it will do it clinical examination with seven people between 50 and 69 years.
Parkinson's disease is characterized by neuronal degeneration, With symptoms that progressively aggravate, such as jitter, muscle stiffness, and loss of body capacity to move.
Read Here: Parkinson's Disease Has Occurred In The Addition
It affects more than ten million people in the world, according to the American Parkinson's Disease Foundation. in Colombia has more than 220,000 people with this disease, according to the Colombian Association of Neurology. The currently available therapies "improve the symptoms without slowing the progression of the disease", explains the foundation.
New investigations aimed at turning the evil. Ago Clinical trial in humans experiment was done with monkeys with stem cells of human origin which enabled the enhancement of the ability to initiate primates affected by some type of Parkinson's disease, according to a study published at the end of August 2017 in a science journal Nature.
Two years survival of transplanted cells was monitored by injection into the brain of the primate and no tumor was detected.
Stimulated pluripotent stem cells (iPSs) are adult cells reduced to their almost embryonic state to generate four genes (normally inactive in adults). This genetic manipulation restores the ability to produce any cell to the site where they are transplanted.
The use of iPS cells does not represent significant ethical problems, unlike stem cells obtained from human embryos.